• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 7th September 2010

Value Based Pricing in the UK

Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article in the British Journal of Clinical Pharmacology, Prof Adrian Towse examines the issues from…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article in the British Journal of Clinical Pharmacology, Prof Adrian Towse examines the issues from a UK perspective. Managing and containing costs in the NHS is a perennial challenge. Far less clear is how to accomplish this while still ensuring sufficient incentives for timely access to new medical therapies, particularly new medicines.

Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances.  In a recent article in the British Journal of Clinical Pharmacology, Prof Adrian Towse examines the issues from a UK perspective.  Managing and containing costs in the NHS is a perennial challenge.  Far less clear is how to accomplish this while still ensuring sufficient incentives for timely access to new medical therapies, particularly new medicines.  Health technology assessment, he believes, is an important tool, but only if used appropriately and within its limits.

In the UK, prices for medicines are guided by a voluntary agreement, renewed and revised periodically, between the government and the pharmaceutical industry, the Pharmaceutical Price Regulation Scheme (PPRS).  Prior to the last round of negotiations, the Office of Fair Trading (OFT) published a report proposing that the PPRS profit-control approach be replaced by a ‘value based pricing’ (VBP) approach. The National Institute for Health and Clinical Excellence (NICE) would indicate prices at which a product would be cost effective in different patient subgroups; the Department of Health (DH) would then negotiate a price with the company.  In a second phase, NICE would be merged with its Scottish and Welsh equivalents and be given DH’s power to set prices for medicines when used by the NHS.  An explicit cost per quality adjusted life year (QALY) threshold (not a range) would be negotiated periodically with the pharmaceutical industry under a VBP-PPRS agreement.

According to Prof Towse, ‘combining price setting with the scientific task of assessing cost and effects risks biasing NICE’s judgments’ and introducing political opportunism. From a short-term NHS perspective, a low price and the use of a new technology could be achieved by ensuring that NICE’s assessments are ‘”rigged” to justify demanding a lower price than the drug is worth to the NHS’.  Introducing such potential bias would substantially increase uncertainty for pharmaceutical companies.  Prof Towse provides a comprehensive overview in the article of the numerous uncertainties that companies face already.

The 2009 PPRS agreement maintained the separation between scientific review and price decision making, stating that ‘NICE does not negotiate, set or publicly indicate prices’.  Two new value-focused measures, both to be reviewed within two years, were agreed.  The first,  ‘Flexible Pricing’, provides for minimal DH involvement and an ‘automatic’ adjustment in UK list prices based on new evidence of clinical and cost effectiveness.  NICE’s review can veto a UK price increase for an existing indication, but not for a new one.  The second, Patient Access Schemes, entail the company and the DH agreeing on an arrangement for making available a medicine initially turned down by NICE — essentially a ‘fast track’ re-review. In the article, Prof Towse explores how any of the parties might seek to ‘game’ the new measures and the counters for such attempts. Prof Towse also notes that, in discussions through the Office of Life Sciences since the PPRS agreement, a NICE-administered ‘innovation pass’ mechanism has been established.  In essence a form of conditional approval, this allows early access to a small number of new drugs with limited but highly positive initial evidence of efficacy.  These would be available for up to three years while additional evidence is collected, with a pre-agreed ‘exit strategy’ in the event of NICE non-approval.

Although it is far too early to draw conclusions about the value of these new approaches, Prof Towse notes that they can ‘lead to forms of “coverage with evidence development” in the UK that will enable patients to access medicines whilst underlying uncertainty about value is reduced’.  Getting ‘value based pricing’ right, he argues, is essential to timely access to new medicines for patients in the UK and to ensuring that the UK market remains part of companies’ R&D and portfolio management decisions.  ‘Getting it wrong, by resisting coverage with evidence development and introducing government price-setting, risks side-lining the UK’.  If the UK ceases to be an early launch market, access will be delayed, the NHS will become irrelevant in companies’ R&D decision making, and the UK’s biomedical science base will erode.

Towse, A. (2010) Value based pricing, research and development, and patient access schemes.  Will the United Kingdom get it right or wrong? British Journal of Clinical Pharmacology. 70(3), 360-366.

  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!